Eli Lilly’s Cyramza Approved for HCC Patients, Boxed Warning Label Removed by FDA
The drug was approved as a second-line treatment for HCC patients who have an alpha-fetoprotein biomarker.
The drug was approved as a second-line treatment for HCC patients who have an alpha-fetoprotein biomarker.